Xenon gas
Phase 1Biologic
Xenon gas is one of 87 biologic programs targeting Lung Disease. It is currently in Phase 1.
2
Indications
3
Total Trials
0
Active Trials
86
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
245 competitors in Brain Injury
#DrugCompanyPhaseTrials
1Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
Zyloprim
Alnylam PharmaceuticalsPhase 3
Brintellix
TakedaPhase 3
Epsom Salt
FFresenius Kabi Oncology Ltd.
Phase 3
Cyklokapron
AAmring
Phase 3
Nuvigil
NNuvo Research GmbH
Phase 3
Prometrium
FerringPhase 3
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Rocephin
CConrado Roberto Hoffmann Filho
Phase 3
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Brain Injury2 trials
Xenon and Cooling Therapy in Babies at High Risk of Brain Injury Following Poor Condition at Birth
Completed·UUniversity Hospitals Bristol and Weston NHS Foundation Trust·Phase 2·NCT02071394·50 enrolled
Xenon and Cooling Therapy in Babies at High Risk of Brain Injury Following Poor Condition at Birth
Completed·UUniversity Hospitals Bristol and Weston NHS Foundation Trust·Phase 1/2·NCT01545271·32 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Xenon gas. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details